Intracellular accumulation of a mild-denatured monomer of the human PrP fragment 90-231, as possible mechanism of its neurotoxic effects

Journal of Neurochemistry

Volumn 103, Issue 6, 2007, Pages 2597-2609

  Chiovitti, Katia ^a   Corsaro, Alessandro ^b   Thellung, Stefano ^b   Villa, Valentina ^b   Paludi, Domenico ^c   D'Arrigo, Cristina ^d   Russo, Claudio ^e   Perico, Angelo ^d   Ianieri, Adriana ^f   Di Cola, Domenico ^a   Vergara, Alberto ^c   Aceto, Antonio ^a   Florio, Tullio ^a,b  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF TERAMO   (Italy)

^d CNR   (Italy)

^e UNIVERSITY OF MOLISE   (Italy)

^f UNIVERSITY OF PARMA   (Italy)

Author keywords

Intracellular internalization; Neurotoxicity; Protein aggregation; PrP90 231

Indexed keywords

MONOMER; PRION PROTEIN; PROTEIN PRP 90 231; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; ISOPROTEIN; NEUROTOXIN; PEPTIDE FRAGMENT; PRION PROTEIN (90 231); PRION PROTEIN (90-231);

AEROBIC METABOLISM; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; DENATURATION; GEL FILTRATION; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; INCUBATION TIME; LIGHT SCATTERING; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; OLIGOMERIZATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN INTERACTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; SPECTROSCOPY; CELL SURVIVAL; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; HEAT; INTRACELLULAR FLUID; METABOLISM; PHYSIOLOGY; PRION; PROTEIN DENATURATION; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL SURVIVAL; HEAT; HUMANS; INTRACELLULAR FLUID; NEUROTOXINS; PEPTIDE FRAGMENTS; PRIONS; PROTEIN DENATURATION; PROTEIN ISOFORMS;

EID: 40549105157     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2007.04965.x     Document Type: Article

References (51)

1. Aceto A., Sacchetta P., Bucciarelli T., Dragani B., Angelucci S., Radatti G. L. and Di Ilio C. (1995) Structural and functional properties of the 34-kDa fragment produced by the N-terminal chymotryptic cleavage of glutathione transferase P1-1. Arch. Biochem. Biophys. 316, 873-878.
2. Aguzzi A. (2006) Prion diseases of humans and farm animals: epidemiology, genetics, and pathogenesis. J. Neurochem. 97, 1726-1739.
3. Aguzzi A., Glatzel M., Montrasio F., Prinz M. and Heppner F. L. (2001) Interventional strategies against prion diseases. Nat. Rev. Neurosci. 2, 745-749.
4. Baskakov I. V., Legname G., Prusiner S. B. and Cohen F. E. (2001) Folding of prion protein to its native alpha-helical conformation is under kinetic control. J. Biol. Chem. 276, 19687-19690.
5. Baskakov I. V., Legname G., Baldwin M. A., Prusiner S. B. and Cohen F. E. (2002) Pathway complexity of prion protein assembly into amyloid. J. Biol. Chem. 277, 21140-21148.
6. Bocharova O. V., Breydo L., Parfenov A. S., Salnikov V. V. and Baskakov I. V. (2005) In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc). J. Mol. Biol. 346, 645-659.
7. Brown D. R., Schmidt B. and Kretzschmar H. A. (1996) Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Nature 380, 345-347.
8. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J., Taddei N., Ramponi G., Dobson C. M. and Stefani M. (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416, 507-511.
9. Chen S. G., Teplow D. B., Parchi P., Teller J. K., Gambetti P. and Autilio-Gambetti L. (1995) Truncated forms of the human prion protein in normal brain and in prion diseases. J. Biol. Chem. 270, 19173-19180.
10. Chiesa R. and Harris D. A. (2001) Prion diseases: what is the neurotoxic molecule? Neurobiol. Dis. 8, 743-763.
11. Corsaro A., Thellung S., Russo C. et al. (2002) Expression in E. coli and purification of recombinant fragments of wild type and mutant human prion protein. Neurochem. Int. 41, 55-63.
12. Corsaro A., Thellung S., Villa V. et al. (2003) Prion protein fragment 106-126 induces a p38 MAP kinase-dependent apoptosis in SH-SY5Y neuroblastoma cells independently from the amyloid fibril formation. Ann. N. Y. Acad. Sci. 1010, 610-622.
13. Corsaro A., Paludi D., Villa V. et al. (2006) Conformation dependent pro-apoptotic activity of the recombinant human prion protein fragment 90-231. Int. J. Immunopathol. Pharmacol. 19, 339-356.
14. Fioriti L., Angeretti N., Colombo L. et al. (2007) Neurotoxic and gliotrophic activity of a synthetic peptide homologous to Gerstmann-Straussler- Scheinker disease amyloid protein. J. Neurosci. 27, 1576-1583.
15. Florio T., Thellung S., Amico C., Robello M., Salmona M., Bugiani O., Tagliavini F., Forloni G. and Schettini G. (1998) Prion protein fragment 106-126 induces apoptotic cell death and impairment of L-type voltage-sensitive calcium channel activity in the GH3 cell line. J. Neurosci. Res. 54, 341-352.
16. Florio T., Paludi D., Villa V. et al. (2003) Contribution of two conserved glycine residues to fibrillogenesis of the 106-126 prion protein fragment. Evidence that a soluble variant of the 106-126 peptide is neurotoxic. J. Neurochem. 85, 62-72.
17. Forloni G., Angeretti N., Chiesa R., Monzani E., Salmona M., Bugiani O. and Tagliavini F. (1993) Neurotoxicity of a prion protein fragment. Nature 362, 543-546.
18. Gallo M., Paludi D., Cicero D. O. et al. (2005) Identification of a conserved N-capping box important for the structural autonomy of the prion alpha 3-helix: the disease associated D202N mutation destabilizes the helical conformation. Int. J. Immunopathol. Pharmacol. 18, 95-112.
19. Goldberg A. L. (2003) Protein degradation and protection against misfolded or damaged proteins. Nature 426, 895-899.
20. Haass C. and Selkoe D. J. (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112.
21. Hetz C., Russelakis-Carneiro M., Maundrell K., Castilla J. and Soto C. (2003) Caspase-12 and endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein. EMBO J. 22, 5435-5445.
22. Jackson G. S., Hill A. F., Joseph C., Hosszu L., Power A., Waltho J. P., Clarke A. R. and Collinge J. (1999) Multiple folding pathways for heterologously expressed human prion protein. Biochim. Biophys. Acta 1431, 1-
23. Kazlauskaite J., Young A., Gardner C. E., Macpherson J. V., Venien-Bryan C. and Pinheiro T. J. (2005) An unusual soluble beta-turn-rich conformation of prion is involved in fibril formation and toxic to neuronal cells. Biochem. Biophys. Res. Commun. 328, 292-305.
24. Kourie J. I. and Henry C. L. (2002) Ion channel formation and membrane-linked pathologies of misfolded hydrophobic proteins: the role of dangerous unchaperoned molecules. Clin. Exp. Pharmacol. Physiol. 29, 741-753.
25. Kristiansen M., Deriziotis P., Dimcheff D. E. et al. (2007) Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol. Cell 26, 175-188.
26. Leffers K. W., Schell J., Jansen K., Lucassen R., Kaimann T., Nagel-Steger L., Tatzelt J. and Riesner D. (2004) The structural transition of the prion protein into its pathogenic conformation is induced by unmasking hydrophobic sites. J. Mol. Biol. 344, 839-853.
27. Legname G., Baskakov I. V., Nguyen H. O., Riesner D., Cohen F. E., DeArmond S. J. and Prusiner S. B. (2004) Synthetic mammalian prions. Science 305, 673-676.
28. Mehlhorn I., Groth D., Stockel J. et al. (1996) High-level expression and characterization of a purified 142-residue polypeptide of the prion protein. Biochemistry 35, 5528-5537.
29. Muller W. E., Ushijima H., Schroder H. C., Forrest J. M., Schatton W. F., Rytik P. G. and Heffner-Lauc M. (1993) Cytoprotective effect of NMDA receptor antagonists on prion protein (PrionSc)-induced toxicity in rat cortical cell cultures. Eur. J. Pharmacol. 246, 261-267.
30. Novitskaya V., Bocharova O. V., Bronstein I. and Baskakov I. V. (2006) Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. J. Biol. Chem. 281, 13828-13836. Epub 12006 Mar 13822.
31. Prusiner S. B. (1982) Novel proteinaceous infectious particles cause scrapie. Science 216, 136-144.
32. Prusiner S. B. (1991) Molecular biology of prion diseases. Science 252, 1515-1522.
33. Prusiner S. B. (1998) Prions. Proc. Natl Acad. Sci. USA 95, 13363-13383.
34. Prusiner S. B., McKinley M. P., Bowman K. A., Bolton D. C., Bendheim P. E., Groth D. F. and Glenner G. G. (1983) Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 35, 349-358.
35. Rezaei H., Eghiaian F., Perez J., Doublet B., Choiset Y., Haertle T. and Grosclaude J. (2005) Sequential generation of two structurally distinct ovine prion protein soluble oligomers displaying different biochemical reactivities. J. Mol. Biol. 347, 665-679.
36. Rideout H. J., Lang-Rollin I. and Stefanis L. (2004) Involvement of macroautophagy in the dissolution of neuronal inclusions. Int. J. Biochem. Cell Biol. 36, 2551-2562.
37. Ross C. A. and Poirier M. A. (2004) Protein aggregation and neurodegenerative disease. Nat. Med. 10(Suppl.), S10-S17.
38. Rubinsztein D. C. (2006) The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443, 780-786.
39. Salmona M., Malesani P., De Gioia L. et al. (1999) Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106-126. Biochem. J. 342, 207-214.
40. Satoh K., Muramoto T., Tanaka T., Kitamoto N., Ironside J. W., Nagashima K., Yamada M., Sato T., Mohri S. and Kitamoto T. (2003) Association of an 11-12 kDa protease-resistant prion protein fragment with subtypes of dura graft-associated Creutzfeldt-Jakob disease and other prion diseases. J. Gen. Virol. 84, 2885-2893.
41. Silveira J. R., Raymond G. J., Hughson A. G., Race R. E., Sim V. L., Hayes S. F. and Caughey B. (2005) The most infectious prion protein particles. Nature 437, 257-261.
42. Sokolowski F., Modler A. J., Masuch R., Zirwer D., Baier M., Lutsch G., Moss D. A., Gast K. and Naumann D. (2003) Formation of critical oligomers is a key event during conformational transition of recombinant syrian hamster prion protein. J. Biol. Chem. 278, 40481-40492.
43. Swietnicki W., Morillas M., Chen S. G., Gambetti P. and Surewicz W. K. (2000) Aggregation and fibrillization of the recombinant human prion protein huPrP90-231. Biochemistry 39, 424-431.
44. Taylor J. P., Hardy J. and Fischbeck K. H. (2002) Toxic proteins in neurodegenerative disease. Science 296, 1991-1995.
45. Thellung S., Florio T., Corsaro A., Arena S., Merlino M., Salmona M., Tagliavini F., Bugiani O., Forloni G. and Schettini G. (2000a) Intracellular mechanisms mediating the neuronal death and astrogliosis induced by the prion protein fragment 106-126. Int. J. Dev. Neurosci. 18, 481-492.
46. Thellung S., Florio T., Villa V. et al. (2000b) Apoptotic cell death and impairment of L-type voltage-sensitive calcium channel activity in rat cerebellar granule cells treated with the prion protein fragment 106-126. Neurobiol. Dis. 7, 299-309.
47. Thellung S., Villa V., Corsaro A., Arena S., Millo E., Damonte G., Benatti U., Tagliavini F., Florio T. and Schettini G. (2002) p38 MAP kinase mediates the cell death induced by PrP106-126 in the SH-SY5Y neuroblastoma cells. Neurobiol. Dis. 9, 69-81.
48. Torrent J., Alvarez-Martinez M. T., Heitz F., Liautard J. P., Balny C. and Lange R. (2003) Alternative prion structural changes revealed by high pressure. Biochemistry 42, 1318-1325.
49. Villa V., Corsaro A., Thellung S. et al. (2006) Characterization of the proapoptotic intracellular mechanisms induced by a toxic conformer of the recombinant human prion protein fragment 90-231. Ann. N. Y. Acad. Sci. 1090, 276-291.
50. Zhang H., Stockel J., Mehlhorn I., Groth D., Baldwin M. A., Prusiner S. B., James T. L. and Cohen F. E. (1997) Physical studies of conformational plasticity in a recombinant prion protein. Biochemistry 36, 3543-3553.
51. Zou W. Q., Capellari S., Parchi P., Sy M. S., Gambetti P. and Chen S. G. (2003) Identification of novel proteinase K-resistant C-terminal fragments of PrP in Creutzfeldt-Jakob disease. J. Biol. Chem. 278, 40429-40436.